Cagrilintide is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. CagriSema is combined with Cagrilintide and Semaglutide.
The clinical phase II trial of CagriSema in diabetic patients was successfully completed with superior weight loss and glucose-lowering effects compared to simethicone. The trial included 92 patients with type 2 diabetes with overweight, randomized equally into 3 groups: CagriSema injection (2.4 mg of simeplutide and 2.4 mg of cagrilintide), 2.4 mg of simeplutide alone, and 2.4 mg of cagrilintide alone. the treatment duration was 32 weeks, and subjects had a mean baseline HbA1c was 8.4% and mean baseline weight was 106 kg.
The results showed that in terms of weight loss, CagriSema injection significantly outperformed simepaglutide (5.1%) and cagrilintide (8.1%) by 15.6% of body weight loss.
Kruse T, Hansen JL, Dahl K, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021;64(15):11183-11194. doi:10.1021/acs.jmedchem.1c00565
Dehestani B, Stratford NR, le Roux CW. Amylin as a Future Obesity Treatment. J Obes Metab Syndr. 2021;30(4):320-325. doi:10.7570/jomes21071
Fletcher MM, Keov P, Truong TT, et al. AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. J Pharmacol Exp Ther. 2021;377(3):417-440. doi:10.1124/jpet.121.000567